SCHEMBL3344933

SCHEMBL3344933

CS(=O)(=O)c1nc(Nc2ccc(F)c(Cl)c2)ncc1-c1cncnc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.47
STK17A Q9UEE5 2/20 0.44
STK17B O94768 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
APP P05067 2/20 0.42
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
GRM4 Q14833 1/20 0.40
CSNK2A1 P68400 1/20 0.40
ABL1 P00519 1/20 0.40
BCR P11274 1/20 0.40
EGFR P00533 1/20 0.40
AXL P30530 2/20 0.39
GLO1 Q04760 1/20 0.39
SOS1 Q07889 1/20 0.39
ULK1 O75385 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3345887 0.87 APP (0.45) MAPK1STK17ASTK17BCA12CA1
SCHEMBL13348282 0.86 CSNK2A1 (0.49) MAPK1STK17ACSNK2A1ABL1BCR
SCHEMBL3344565 0.82 FGFR1 (0.41) STK17ASTK17BCA2CSNK2A1ABL1
SCHEMBL3344725 0.81 CA12 (0.50) MAPK1STK17ASTK17BCA12CA1
SCHEMBL3350970 0.81 CSNK2A1 (0.43) MAPK1STK17ASTK17BCA12CA1
SCHEMBL13348245 0.81 MAPK1 (0.49) MAPK1STK17ASTK17BCA12CA1
SCHEMBL13310846 0.80 BCL6 (0.50) MAPK1STK17ASTK17BAPPGRM4
SCHEMBL3450596 0.79 STK17A (0.55) MAPK1STK17ASTK17BAXLGLO1
SCHEMBL3344327 0.78 PIM2 (0.40) MAPK1STK17ASTK17BCA12CA1
SCHEMBL3344324 0.78 PIM2 (0.40) MAPK1STK17ASTK17BCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD MAPK1 2905/4885STK17A 1984/4885STK17B 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.